Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386111 · ClinicalTrials.gov registry record · Phase 1
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase 1 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02386111 is a Phase 1 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT02386111, a Phase 1 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.
Interventions
- DRUG Combination of varlilumab and sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-11-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02386111
The ClinicalTrials.gov registry entry for NCT02386111 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combination of varlilumab and sunitinib is the first listed.
NCT02386111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02386111 about?
NCT02386111 is a clinical study titled "A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma". This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and sunitinib. The study will enroll patients with metastatic clear cell renal cell carcinoma.
What is the current status of trial NCT02386111?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2015-05. Estimated completion is 2017-11-03.
What interventions are being tested in trial NCT02386111?
The interventions under investigation include: Combination of varlilumab and sunitinib (DRUG).
Who is sponsoring clinical trial NCT02386111?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.